Medpace Holdings Inc vs Global X Defense Tech ETF — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Global X Defense Tech ETF trades at $70.68. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | SHLD | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $620.59 | $78.02 |
52-Week Low | $393.42 | $58.20 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
SHLD (Global X Defense Tech ETF) trades at $70.15, up 0.43% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from increased institutional interest with multiple firms raising stakes in Q2 2026, while geopolitical tensions and rising global defense spending underpin sector tailwinds. However, key oscillators show neutral to overbought conditions with RSI levels above 78, suggesting potential near-term consolidation.
The defense technology sector outlook remains favorable amid elevated military budgets worldwide, though SHLD faces competition from similar ETFs and sensitivity to geopolitical developments. Current technical strength supports bullish momentum, but investors should monitor RSI levels for overextension risks amid evolving defense policy shifts.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →